Insmed's Supplemental New Drug Application (sNDA) for ARIKAYCE, an inhaled antibiotic for Mycobacterium avium complex (MAC) lung disease, has been accepted by the FDA with Priority Review and a target decision date of January 28, 2027. The full approval application is based on positive Phase 3b ENCORE study results showing significant improvements in respiratory symptoms and culture conversion compared to standard therapy. Full approval could allow ARIKAYCE to be used earlier in the disease course, benefiting more patients. Insmed also plans to seek label expansion in Japan based on these data.
The FDA's Priority Review of Insmed's sNDA for ARIKAYCE provides context for healthcare sector interest. For readers following health-sector stocks, 46 of 92 US stocks traded on Pluang rose and 29 fell today. Notable movers include Novo Nordisk A/S (NVO) at USD 41.22 with a -4.67% change, Summit Therapeutics Inc (SMMT) at USD 18.61 up 4.26%, and AbCellera Biologics Inc (ABCL) at USD 13.07 up 3.48%, as of Sep 21, 2026 17:21 WIB.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
